Sue Hohenleitner, CPA, CMA

Sue has served as Ardelyx’s Chief Financial Officer since October 2025, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development within the healthcare industry. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Prior to joining Ardelyx, Sue enjoyed a 28-year career at Johson & Johnson (J&J) where she led multiple finance organizations in areas such as supply chain, innovation, commercial, business development, investor relations, acquisitions and divestitures, and finance planning and analysis. In her most recent role as Vice President and Chief Financial Officer of J&J Innovative Medicine North America, Sue led a number of strategic initiatives that resulted in greater efficiencies, effectiveness and funding for growth. Sue was also a critical partner during the acquisition of two significant deals which resulted in successful commercial launches.

Sue is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She was also a Board Member of the Institute of Management Accountants (IMA) where she provided oversight and strategy planning for the IMA and its members. Sue was named a Top 25 CFO in Biotech by Business & Investing and was recently honored by her alma mater, La Salle University, with their highest leadership award for contributions to the university, their students and the community.

She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Sue began her career as an auditor at Arthur Andersen, LLP in Philadelphia.